---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-24-000114"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:40:30.183323+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas achieves in vivo preclinical proof of concept for sickle cell; seeks partner for reni-cel

## Summary
- Achieved 29% HSPC editing and 20% HbF-expressing red blood cells in humanized mice after single dose using proprietary tLNP.
- Initiated process to partner or out-license reni-cel; engaged Moelis & Company to lead global process.
- Q3 2024 cash, equivalents, and marketable securities ~$265M; ~$320M after $57M upfront from DRI Healthcare.
- On track to present substantive RUBY trial SCD data at ASH December 2024; EdiTHAL data by year-end 2024.
- Company will not host Q3 2024 earnings call; strategic update webinar held October 22, 2024.

## SEC filing metadata
- accession: 0001650664-24-000114
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000114/0001650664-24-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000114/edit-20241022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-24-000114
- JSON: https://secwatch.observer/filing/0001650664-24-000114.json
- Plain text: https://secwatch.observer/filing/0001650664-24-000114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.